Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiotensin II and nitric oxide interaction.

Marc de Gasparo1

  • 1MG Consulting Co, Rossemaison, Switzerland. m.de_gasparo@bluewin.ch

Heart Failure Reviews
|October 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.

British journal of pharmacology·2023
Same author

Asymmetric Interaction of Neuropeptidase Activities between Cortico-Limbic Structures, Plasma and Cardiovascular Function after Unilateral Dopamine Depletions of the Nigrostriatal System.

Biomedicines·2022
Same author

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.

British journal of pharmacology·2021
Same author

Interaction between Angiotensinase Activities in Pituitary and Adrenal Glands of Wistar-Kyoto and Spontaneously Hypertensive Rats under Hypotensive or Hypertensive Treatments.

International journal of molecular sciences·2021
Same author

The Type of Fat in the Diet Influences the Behavior and the Relationship Between Cystinyl and Alanyl Aminopeptidase Activities in Frontal Cortex, Liver, and Plasma.

Frontiers in molecular biosciences·2020
Same journal

Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.

Heart failure reviews·2026
Same journal

Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.

Heart failure reviews·2026
Same journal

Beyond the right ventricle: left heart involvement in pulmonary arterial hypertension.

Heart failure reviews·2026
Same journal

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same journal

Correction to: Left atrial shunting devices: why, what, how, and… when?

Heart failure reviews·2026
Same journal

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
See all related articles

Nitric oxide (NO) degradation by reactive oxygen species (ROS) contributes to cardiovascular disease. Blocking the Angiotensin II AT(1) receptor may restore NO function and counteract endothelial dysfunction.

Area of Science:

  • Cardiovascular Science
  • Molecular Medicine
  • Biochemistry

Background:

  • Nitric oxide (NO) degradation, driven by reactive oxygen species (ROS), is a key factor in cardiovascular diseases.
  • Superoxide-producing enzymes like NADPH oxidase and xanthine oxidase generate ROS, leading to NO inactivation.
  • Angiotensin II, via the AT(1) receptor, stimulates NADPH oxidase, impairing endothelial function and promoting vascular pathology.

Purpose of the Study:

  • To investigate the role of Angiotensin II signaling in endothelial dysfunction.
  • To explore the counterbalance effect of the AT(2) receptor against AT(1) receptor-mediated damage.
  • To evaluate the therapeutic potential of AT(1) receptor antagonists in mitigating NO degradation.

Main Methods:

  • Review of preclinical and clinical studies on Angiotensin II signaling and endothelial function.

Related Experiment Videos

  • Analysis of the molecular mechanisms involving NADPH oxidase, ROS, and NO synthase.
  • Examination of the proposed role of the AT(2) receptor and bradykinin in vascular homeostasis.

    • Main Results:

    • Angiotensin II AT(1) receptor stimulation increases NADPH oxidase activity, leading to NO inactivation.
    • This pathway contributes to endothelial dysfunction, vascular smooth muscle cell hypertrophy, proliferation, migration, and inflammation.
    • The AT(2) receptor may counteract these effects through bradykinin and NO synthase stimulation.

    Conclusions:

    • The Angiotensin II AT(1) receptor plays a significant role in endothelial dysfunction via NO degradation.
    • AT(2) receptor activation offers a potential counter-regulatory mechanism.
    • Blocking the AT(1) receptor with antagonists presents a promising therapeutic strategy for cardiovascular diseases associated with NO impairment.